This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

InspireMD To Announce Six-Month Results From The MGuard™ Embolic Protection Stent (EPS) MASTER Trial At EuroPCR

BOSTON and TEL AVIV, Israel, May 16, 2013 /PRNewswire/ --

  - Strong Conference Presence to Include Presentations/Educational Events Featuring the MGuard™ Embolic Protection Stent-

  - Company to Host Conference Call on Thursday, May 23 rd   to Review MASTER Data -

InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection stents, today announced a robust schedule of educational events and data presentations at EuroPCR, culminating in the first presentation of 6-month results from the MASTER ( MGuardfor Acute STElevation Reperfusion) trial of the Company's MGuard™ Embolic Protection Stent (EPS).

EuroPCR is the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI) and takes place in Paris, at the Palais Des Congrès,from May 21-24, 2013.

Gregg W. Stone M.D., the MASTERstudy chairman and the Director of the Cardiovascular Research and Education Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/ Columbia University Medical Center, said, "In these STEMI patients, embolic protection is an unmet need that is not addressed by current bare metal or drug eluting coronary stents. The clinical evidence supporting the benefits of using the MGuard EPS stent in STEMI patientscontinues to grow. This year's EuroPCR meeting will add important new data underlining the protective benefits of MGuard EPS six months post-procedure."

Inspire MD STEMI Symposium

Thursday, May 23, 2013

12:00 CET, Room 242AB

The Embolic Protection Stent - Beyond current techniques:

A More Effective Solution in STEMI Primary PCI

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs